954 Stock Overview
A biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Awakn Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.051 |
| 52 Week High | CA$0.15 |
| 52 Week Low | CA$0.033 |
| Beta | 2.68 |
| 1 Month Change | 0.98% |
| 3 Month Change | 39.19% |
| 1 Year Change | -41.81% |
| 3 Year Change | -97.32% |
| 5 Year Change | n/a |
| Change since IPO | -96.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 954 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | -0.4% |
| 1Y | -41.8% | -10.2% | 7.9% |
Return vs Industry: 954 underperformed the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: 954 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 954 volatility | |
|---|---|
| 954 Average Weekly Movement | 76.4% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 954's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 954's weekly volatility has increased from 64% to 76% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Anthony Tennyson | awaknlifesciences.com |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company’s lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.
Awakn Life Sciences Corp. Fundamentals Summary
| 954 fundamental statistics | |
|---|---|
| Market cap | €2.66m |
| Earnings (TTM) | -€1.74m |
| Revenue (TTM) | €38.40k |
69.2x
P/S Ratio-1.5x
P/E RatioIs 954 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 954 income statement (TTM) | |
|---|---|
| Revenue | CA$57.16k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$57.16k |
| Other Expenses | CA$2.65m |
| Earnings | -CA$2.60m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,543.93% |
| Debt/Equity Ratio | 0% |
How did 954 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/04 07:34 |
| End of Day Share Price | 2024/12/16 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Awakn Life Sciences Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Andrew Partheniou | Stifel Canada |